We are proud to announce the new indication Lenvatib, approved under the ANMAT Approval Deposition: 7839/2019.
Differentiated thyroid carcinoma
Indicated for the treatment of adult patients with differentiated thyroid carcinoma (papillary, follicular or Hürthle cell CDT) in progression, locally advanced or metastatic, who resist to treatment with rRadioactive Iodine (RAI).
Renal cell carcinoma
It is indicated in combination with everolimus for the treatment of patients with advanced Renal cell carcinoma insufficiency (RCC) after prior therapy with endothelial vascular growth factor (VEGF).
Hepatocellular carcinoma
It is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic treatment.